Jeffrey Bluestone hands Sonoma CEO post to Stephen Dillynews2025-11-17T16:26:56+00:00November 17th, 2025|Endpoints News|
How the Lilly-Adverum deal came together; Captain T Cell reels in €20Mnews2025-11-17T16:10:06+00:00November 17th, 2025|Endpoints News|
Terray Therapeutics unveils AI platform EMMI, selection modelnews2025-11-17T16:00:31+00:00November 17th, 2025|Endpoints News|
Merck is still hunting for deals after two major bolt-on acquisitions this yearnews2025-11-17T15:58:32+00:00November 17th, 2025|Endpoints News|
J&J to buy Halda for $3.05B, adding startup’s RIPTAC cancer drugnews2025-11-17T14:27:30+00:00November 17th, 2025|Endpoints News|
Solve Therapeutics rakes in $120M for two mystery ADCsnews2025-11-17T13:03:19+00:00November 17th, 2025|Endpoints News|
Artios Pharma raises $115M for DNA damage response programsnews2025-11-17T13:00:52+00:00November 17th, 2025|Endpoints News|
Nuvalent shares Phase 1/2 data for ALK inhibitor that could battle with Pfizer’s Lorbrenanews2025-11-17T11:50:47+00:00November 17th, 2025|Endpoints News|
Lilly makes up to $2.6B pact with South Korean biotech ABL Bionews2025-11-17T10:28:16+00:00November 17th, 2025|Endpoints News|
Genmab cans another ADC from ProfoundBio deal in area of J&J’s Ambrx buyoutnews2025-11-17T10:04:19+00:00November 17th, 2025|Endpoints News|
